Array
(
    [0] => 
    [1] => department-of-laboratory-and-transfusion-services
    [2] => molecular-laboratory
    [3] => 
)

Molecular Laboratory

molecular laboratory

Molecular diagnostics at RGCI&RC is a NABL accredited laboratory developed under the leadership of Dr Anurag Mehta. It is one of the most dynamic and transformative departments with interplay of genomic knowledge, laboratory medicine and state of art technology. Molecular laboratory menu has steadily grown in all applications ranging from infectious disease, genetic, and oncology testing. It currently offers more than 100 tests (Directory of Services). This varied portfolio is realized by diverse complex machinery facilitating tests for solid organ and hematological malignancies. The available testing platforms range from real time PCR for single gene testing, Fluorescent In situ Hybridization, Sanger sequencing for miscellaneous applications including tests based on fragment length analysis to high throughput Next Generation sequencing for genetic predisposition, tumor specific panels, tumor mutation burden and liquid biopsy. Laboratory maintains robust external and internal quality assurance programs in the face of emerging technologies, and an evolving regulatory landscape of Precision Medicine biomarkers.

KNOWLEDGE CENTRE

SPECIAL FEATURE – INHERITED CANCER SYNDROMES

1) HEREDITARY BREAST – OVARIAN CANCER SYNDROMES & BRCA TESTING

Cancer occurs by interplay of environment, lifestyle and a minor component of susceptibility in 85% of patients. In minority of individuals with ovarian cancer (~14%) or breast cancer (approximately 5%) or prostate cancer (~ 5%) or pancreatic cancer (~ 5%)   the mutation in the BRCA1 or BRCA2 gene plays an all-important and overarching role. People with BRCA mutations have a lifetime risk of developing these cancers as given in Table below.

Cancer Type Germline BRCA1 mutated Germline BRCA2 mutated No. of times the risk in Germline
BRCA mutated population
Breast Cancer Female 70% 40% 4-5 folds
Ovarian Cancer 50% 30% 30 folds
Breast cancer Male 1.20% 6.8% 50 folds
Prostate Cancer 2% 5% 3-8.6 folds
Pancreatic Cancer 1% 1% 2-4 folds

BRCA testing is recommended for all patients of ovarian cancer, some patients of Breast cancers, all patients with metastatic prostate and pancreatic cancers. It is important to identify if cancer is due to a BRCA1 or BRCA2 mutation because it provides you and your doctors with information that can help treat your cancer and to reduce your risk of future cancer. In addition, BRCA testing is also recommended for First Degree Relatives from 3 generations of a breast / ovarian/ pancreatic/prostate cancer patient with BRCA mutation to identify mutation carriers and encourage them to adopt risk-reducing strategies

TEST MENU

HAEMATOLOGY INFECTIOUS DISEASES SOLID ORGAN MALIGNANCIES
Acute Myeloid Leukemia Translocation Extended Panel Qualitative Test for HPV Extended Solid Tumor Panel-NGS
TPMT Genotyping Quantitative Test for CMV Lynch Syndrome
Quantitative PCR for detection of PML-RARA Quantitative Test for HBV Microsatellite Instability Testing
Qualitative PCR-JAK2 exon 14 BRAF Mutation Analysis By Real Time Qualitative PCR
Comprehensive Myeloid Panel-NGS cKIT Mutation Analysis by Real Time Qualitative PCR
MYD88 p.L265P Mutation Analysis NRAS & KRAS Mutation Testing By Real Time Quantitative PCR

FEATURED DOCTORS

Our Locations
  • Sir Chotu Ram Marg, Sector – 5, Rohini Institutional Area, Rohini, New Delhi, Delhi – 110085, India

    +91-11-47022222 | Fax +91 11 27051037

  • Squadron Leader Mahender Kumar Jain Marg, Block K, Niti Bagh, New Delhi, Delhi 110049

    +91-11-45822222 / +91-11-45822200

All © reserved to Rajiv Gandhi Cancer Institute & Research Centre
Website Designing & SEO by Techmagnate